Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the period of September 2022. The document reports on the outcome of the Company's Annual General Meeting of Shareholders held on September 15, 2022, following a one-week adjournment from the original date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters regarding the shareholder meeting.
Material Changes
There are no financial material changes reported in this document. The primary event is the shareholder approval of all proposals presented at the Annual General Meeting.
Guidance, Outlook, and Management Commentary
The filing confirms that 4,899,609 ordinary shares, representing approximately 12% of the issued and outstanding ordinary shares as of the record date, were present or represented by proxy at the meeting. All proposals were approved by the requisite majority in accordance with the Israeli Companies Law and the Company's articles of association. No specific financial guidance or risk factors are detailed in this specific text.
Important Facts for Investors to Verify
- Verify the specific proposals approved at the September 15, 2022, Annual General Meeting by reviewing the Proxy Statement referenced as Exhibit 99.2 in the August 3, 2022, Form 6-K.
- Confirm the total number of outstanding shares to contextualize the 12% participation rate at the meeting.
- Review subsequent filings for financial performance data, as this Form 6-K contains no financial statements.